ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Health Technology

Sawai Pharmaceutical Co., Ltd.

Business Summary

Sawai Pharmaceutical Co., Ltd. engages in the manufacture and sale of prescription pharmaceutical products. Its products include cardiovascular drugs, antihyperlipidemic agents, diabetes, anticancer drugs, and over-the-counter drugs. The company was founded by Hanpei Sawai and Noyo Sawai on April 1, 1929 and is headquartered in Osaka, Japan.

Financial Highlights

Mar 2019 JPYUSD
Revenue184,341M1,662.30M
Gross Profit69,726M628.75M
Operating income25,848M233.08M
Income before tax25,666M231.44M
Net income19,376M174.72M
EBITDA42,128M379.89M
Diluted EPS442.333.98
Dividends Per Share1351.21
Total Assets372,889M3,368.92M
Total liabilities149,683M1,352.33M
Total equity199,250M1,800.15M
Operating cash flow42,923M387.06M
Currency in JPYCurrency in USD

Historical Data

 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 105,454M 123,492M 132,392M 168,068M 184,341M
Gross Profit 44,701M 50,809M 50,922M 65,195M 69,726M
Operating income 20,688M 23,185M 23,347M 22,176M 25,848M
Income before tax 20,297M 23,091M 22,757M 20,251M 25,666M
Net income 14,053M 17,155M 17,969M 14,017M 19,376M
EBITDA 26,551M 30,229M 31,867M 36,415M 42,128M
Diluted EPS 381.85 465.24 487.09 360.26 442.33
Dividends Per Share 105 120 130 130 135
Total Assets 166,179M 206,492M 225,609M 358,453M 372,889M
Total liabilities 53,781M 80,772M 84,372M 156,011M 149,683M
Total equity 112,398M 125,720M 141,237M 181,350M 199,250M
Operating cash flow 12,112M 19,975M 23,270M 28,472M 42,923M
 Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Revenue 959.92M 1,028.37M 1,222.59M 1,516.41M 1,662.30M
Gross Profit 406.90M 423.11M 470.24M 588.23M 628.75M
Operating income 188.31M 193.07M 215.60M 200.08M 233.08M
Income before tax 184.75M 192.28M 210.15M 182.71M 231.44M
Net income 127.92M 142.85M 165.93M 126.47M 174.72M
EBITDA 241.68M 251.73M 294.28M 328.55M 379.89M
Diluted EPS 3.47 3.87 4.49 3.25 3.98
Dividends Per Share 0.95 0.99 1.20 1.17 1.21
Total Assets 1,385.69M 1,837.19M 2,024.67M 3,370.50M 3,368.92M
Total liabilities 448.45M 718.64M 757.17M 1,466.95M 1,352.33M
Total equity 937.23M 1,118.55M 1,267.49M 1,705.21M 1,800.15M
Operating cash flow 110.25M 166.34M 214.89M 256.89M 387.06M

Valuation Measures

Mar 2019
PER14.48
ROA5.29%
ROE10.18%
Operating margin14.02%
Profit margin10.51%

Key executives

  • President & Representative Director: Mitsuo Sawai
  • Managing Executive Officer, General Manager-R&D: Shoji Yokota
  • Executive Officer & General Manager-Sales: Seiji Nishimura
  • Director & General Manager-Administration: Kazuhiko Sueyoshi
  • Director & Senior Managing Executive Officer: Kenzo Sawai

Shareholders

  • LSV Asset Management (5.0%)
  • The Vanguard Group, Inc. (2.8%)
  • Azimut Capital Management SGR SpA (2.5%)
  • Nomura Asset Management Co., Ltd. (2.4%)
  • SAWAI HIROYUKI FAMILY (2.2%)
  • SAWAI MITSUO (2.1%)
  • SAWAI KENZO (1.9%)
  • Sumitomo Corp. (1.4%)
  • SAWAI HIROYUKI (1.4%)
  • Norges Bank Investment Management (1.3%)

Contact Details

  • Website:http://www.sawai.co.jp
  • Address: 5-2-30 Miyahara, Yodogawa-Ku, Osaka, 532-0003, Japan
  • Phone: +81.6.6105.5711

Related Companies

  • Sawai America, Inc.
  • Sawai USA, Inc.
  • Mitsubishi Tanabe Pharma Factory Ltd. /Kashima Factory/
  • Sawai Pharmaceutical Employee Incentive Plan
  • Km Godo Kaisha
  • Kaken Shoyaku KK
  • Medisa Shinyaku, Inc.
  • Nihon Schering KK /Mobara Factory Operations/

Competitors

  • Xenon Pharmaceuticals Inc.
  • Antares Pharma, Inc.
  • Aeglea BioTherapeutics Inc
  • Albireo Pharma, Inc.
  • Lipocine Inc
  • Mirum Pharmaceuticals, Inc.
  • Supernus Pharmaceuticals, Inc.
  • Zosano Pharma Corp.
Last Updated on 3 Apr, 2020

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Get Unlimited access

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends April 30th

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media